NICE technology appraisal guidance
Issued: June 2009
TA172
Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta172
Important information about this guidance
This guidance was developed using the NICE single technology appraisals process: www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_technology_appraisals.jsp